StockData

ADMA Biologics vs Repligen

ADMA and RGEN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ADMA and RGEN compare

Repligen is the larger company, worth 3.4 times as much as ADMA Biologics ($10.4B against $3.1B).

Repligen grew revenue faster over the last twelve months (13.8% versus 8.0% for ADMA Biologics).

ADMA Biologics keeps more of each dollar of sales as profit, with a net margin of 33.0% compared with −1.5% at Repligen.

ADMA Biologics scores higher on the StockData Score (17 against 7 for Repligen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricADMARGEN
Size and price
Market cap$3.1B$10.4B
Share price$13.63$162.18
Change, 1 year−12.4%6.4%
Change, 5 years840%−43.3%
Beta (5Y)1.481.36
Employees6472,000
StockData Score
Total score17 (better)7
Valuation score5 (better)0
Growth score33
Performance score4 (better)2
Health score5 (better)2
Dividend score00
Valuation
P/E19.5×–
P/S6.0× (better)12.9×
P/B7.5×5.0× (better)
EV/EBITDA13.4× (better)98.9×
P/FCF26.2× (better)97.1×
FCF yield3.8% (better)1.0%
Fair value$18.83$69.93
Margin of safety27.6% (better)−132%
Growth
Revenue growth (TTM)8.0%13.8% (better)
Revenue growth, 5Y average64.6% (better)15.0%
Net income growth (TTM)−19.1% (better)−779%
EPS growth (TTM)−17.6%–
EPS growth, 5Y average–−5.0%
Profitability
Gross margin64.7% (better)53.5%
Operating margin43.8% (better)2.3%
Net margin33.0% (better)−1.5%
FCF margin22.7% (better)13.2%
Return on equity41.9% (better)−0.57%
Return on invested capital45.1% (better)0.71%
Financial health
Debt / equity0.48–
Net debt / EBITDA0.26–
Interest coverage25.4× (better)0.8×
Current ratio6.979.88 (better)
Altman Z-score9.10 (better)8.41
Piotroski F-score57 (better)
Dividends and buybacks
Buyback yield6.1%–
Shareholder yield6.1% (better)0.00%
Ownership
Held by institutions91.8%104%
Held by insiders2.9%0.59%
Insider net buying, 12 months−$3.0M (better)−$6.7M
Superinvestors holding22
Short interest, % of float8.3%11.1%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.